Current Treatment of Chronic Hepatitis B

2009 ◽  
pp. 243-257
Author(s):  
Walid S. Ayoub ◽  
Emmet B. Keeffe
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Current Treatment

scholarly journals [Tenofovir and entecavir for chronic hepatitis B infection treatment: a single-center experience]

2015 ◽  
Vol 9 (4) ◽  
pp. 95-100
Author(s):  
Fabio Tarsetti ◽  
Giuseppe Tarantino ◽  
Piergiorgio Mosca ◽  
Emidio Scarpellini ◽  
Giammarco Fava
Keyword(s):  
Chronic Hepatitis ◽  
Side Effects ◽  
Hepatitis B ◽  
Viral Replication ◽  
Chronic Hepatitis B ◽  
Genetic Resistance ◽  
Abdominal Ultrasound ◽  
Current Treatment ◽  
Hepatitis B Infection ◽  
Chronic Hepatitis B Infection

BACKGROUND AND AIM: The current treatment of chronic hepatitis B infection (CHBV) has achieved several step-ups thanks to the introduction of the new-generation nucleos(t)ide analogs. Entecavir and tenofovir have shown a high genetic resistance barrier and a low rate of side effects. In literature, there are a few studies comparing entecavir and tenofovir in the treatment of CHBV. Thus, we describe the results of our experience in managing CHBV patients with tenofovir vs. entecavir.MATERIALS AND METHODS: We have retrospectively evaluated, from 2007 to date, 20 CHBV patients treated with entecavir and tenofovir. All the patients underwent basal and periodical clinical follow-up, blood tests, virological tests, Fibroscan® test or liver biopsy and also upper abdominal ultrasound examination. Study endpoints were: viral replication inhibition, viral antigens seroconversion and transaminases normalization. Drug-associated side effects were also registered.RESULTS: After 12 weeks of therapy, entecavir and tenofovir lead to HBV-DNA negativization in 44% and 62% of patients, respectively. A case of viral seroconversion for HBeAg and HBsAg was evident in entecavir group, while no cases were registered in tenofovir group. After 12 weeks, 11% of entecavir treated patients and 37% of tenofovir treated patients showed normalization of transaminases.DISCUSSION: Tenofovir seems to exert a better viral replication inhibition (though not statistically significant) and to show transaminases improvement in comparison with entecavir, which, in turn, results more effective in HBeAg/HBsAg seroconversion. Both drugs have a high safety profile in terms of side effects.[Article in Italian]

The risk of hepatocellular carcinoma among chronic hepatitis B virus‐infected patients outside current treatment criteria

2019 ◽  
Vol 26 (12) ◽  
pp. 1465-1472 ◽  
Author(s):  
Dong Hyun Sinn ◽  
Sung Eun Kim ◽  
Beom Kyung Kim ◽  
Ji Hoon Kim ◽  
Moon Seok Choi
Keyword(s):  
Hepatocellular Carcinoma ◽  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Current Treatment ◽  
Chronic Hepatitis B Virus ◽  
B Virus

scholarly journals Current treatment indications and strategies in chronic hepatitis B virus infection

2008 ◽  
Vol 14 (45) ◽  
pp. 6902 ◽  
Author(s):  
George V Papatheodoridis ◽  
Spilios Manolakopoulos ◽  
Athanasios J Archimandritis
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B Virus ◽  
Virus Infection ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Current Treatment ◽  
Hepatitis B Virus Infection ◽  
Treatment Indications ◽  
Chronic Hepatitis B Virus ◽  
B Virus

Current treatment for chronic hepatitis B in Japan

2009 ◽  
Vol 2 (5) ◽  
pp. 325-330 ◽  
Author(s):  
Waka Ohishi ◽  
Kazuaki Chayama
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Current Treatment
Sign in / Sign up

Export Citation Format

Share Document